Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.53 |
| ▸ | ARG1 | P05089 | 2/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31553578 | 1.00 | PNMT (0.53) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL2722949 | 0.98 | PNMT (0.51) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL32676699 | 0.98 | PNMT (0.51) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL32676646 | 0.98 | PNMT (0.51) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL32677111 | 0.98 | PNMT (0.51) | PNMTARG1EGLN1HDAC8ARG2 | |
| SCHEMBL31369850 | 0.94 | PNMT (0.45) | PNMTARG1EGLN1ARG2GAA | |
| Hydrochloric Acid SCHEMBL32676715 | 0.92 | PNMT (0.44) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL32676878 | 0.92 | PNMT (0.44) | PNMTARG1EGLN1HDAC8ARG2 | |
| Hydrochloric Acid SCHEMBL32676729 | 0.92 | PNMT (0.44) | PNMTARG1EGLN1HDAC8ARG2 | |
| SCHEMBL32676768 | 0.86 | PNMT (0.51) | PNMTARG1HDAC8ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3034509-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103249737-A | Borate as arginase inhibitor | MARS INC | 2013-08-14 | — | — | CN | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PNMT 2054/4885ARG1 1/4885EGLN1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.